Aytu BioPharma Q3 FY2025 net income $4M, revenue up 32% YoY to $18.5M

AYTU BIOPHARMA, INC

2025-Q3 EPS reported -$0.22 vs consensus -$0.23 ▲ beat (+6.2%)

Net income of $4.0M ($0.65 basic / $0.21 diluted EPS) vs net loss of $2.9M a year ago.
Total net revenue $18.5M, up 32% YoY; ADHD portfolio up 25% to $15.4M, Pediatric up 77% to $3.1M.
Adjusted EBITDA $3.9M vs $0.9M in Q3 FY2024; operating expenses down 13% YoY.
Cash $18.2M at March 31, 2025; paid down $2.5M in long-term debt during the quarter.
Gross margin 69% vs 74% prior year due to higher-cost ADHD inventory from closed Texas facility; expected to normalize.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.